🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

9,250 results for “IO” Clear

  1. Tarlatamab, OXALIPLATINE VIATRIS 5 mg/ml, poudre pour solution pour perfusion, Dacarbazine "Lipomed", Tecentriq 1 200 mg concentrate for solution for infusion, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion, Temozolomide 100 mg hard capsules, OPDIVO 10 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Topotecan Accord Healthcare 4mg Powder for Concentrate for Solution for Infusion, IRINOTECAN VIATRIS 20 mg/ml, solution à diluer pour per

    CERO THERAPEUTICS HOLDINGS, INC.

    Advanced pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas (NECs)

    phase 3 small molecule active

    1 trial

  2. Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension

    Vanda Pharmaceuticals Netherlands B.V.

    Autism Spectrum Disorder

    phase 3 small molecule active

    1 trial

  3. Tasimelteon Oral Suspension

    Vanda Pharmaceuticals Netherlands B.V.

    Insomnia Disorder

    phase 3 small molecule active

    1 trial

  4. Tebipenem pivoxil, SODIUM CHLORIDE, IMIPENEM AND CILASTATIN , Placebo to match Tebipenem pivoxil, tablet

    Spero Therapeutics

    complicated urinary tract infection (cUTI) or acute pyelonephritis (AP)

    phase 3 small molecule active

    1 trial

  5. Tecentriq 1 200 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    High-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of the bladder (TURBT) and pathological assessment.

    phase 3 small molecule active

    1 trial

  6. Tecentriq 1 200 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Cancer (Future parent protocols may include other cancer that are not included in this section)

    phase 3 small molecule active

    1 trial

  7. Tecentriq 1 200 mg concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion.

    Hoffmann-La Roche

    High-risk hepatocellular carcinoma (HCC)

    phase 3 small molecule active

    1 trial

  8. Tecentriq 1 200 mg concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix

    phase 3 small molecule active

    1 trial

  9. Tecentriq 1 200 mg concentrate for solution for infusion, CISPLATIN , CARBOPLATIN , BNT327, ETOPOSIDE

    BioNTech SE

    English First-line extensive-stage small-cell lung cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  10. Tecentriq 1 200 mg concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Etoposid Hikma 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BI 764532, RoActemra 20 mg/mL concentrate for solution for infusion

    Boehringer Ingelheim

    small cell lung cancer

    phase 3 small molecule active

    1 trial

  11. Tecentriq 1 200 mg concentrate for solution for infusion, Herceptin 600 mg solution for injection in vial, Kadcyla 160 mg powder for concentrate for solution for infusion., Tecentriq placebo

    Hoffmann-La Roche

    Early human epidermal growth factor receptor 2 (HER2) positive breast cancer

    phase 3 small molecule active

    1 trial

  12. Tecentriq 1 200 mg concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Tiragolumab placebo, Tiragolumab

    Hoffmann-La Roche

    Non-squamous non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  13. Tecentriq 1 200 mg concentrate for solution for infusion, LURBINECTEDIN, RO7508182

    Hoffmann-La Roche

    Small-Cell Lung Cancer (SCLC)

    phase 3 small molecule active

    1 trial

  14. Tecentriq 1 200 mg concentrate for solution for infusion, PACLITAXEL, CARBOPLATIN

    CERO THERAPEUTICS HOLDINGS, INC.

    Non Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  15. Tecentriq 840 mg concentrate for solution for infusion

    Novo Nordisk A/S

    Metastatic pancreatic ductal adenocarcinoma (mPDAC)

    phase 3 small molecule active

    1 trial

  16. Tecentriq Placebo, Abraxane 5 mg/ml powder for dispersion for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, Carboplatin 10 mg/ml Intravenous Infusion, Cisplatin 1mg/ml concentrate for solution for infusion

    Hoffmann-La Roche

    Early-Stage Resectable Non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  17. Tecentriq concentrate for solution for infusion placebo 0mg, Tecentriq 840 mg concentrate for solution for infusion

    Hoffmann-La Roche

    High-risk muscle-invasive bladder cancer

    phase 3 small molecule active

    1 trial

  18. Ted sc placebo, VRDN (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor with half-life extension)

    Viridian Pharma Ltd

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  19. Tedizolid (BAY119-2631)

    Bayer HealthCare AG

    Bacterial Infections

    phase 3 small molecule completed

    1 trial

  20. Telavancin

    CUMBERLAND PHARMACEUTICALS INC

    Staphylococcal Skin Infection

    phase 3 small molecule completed

    2 trials

  21. Telitacicept

    Vor Biopharma

    Generalized Myasthenia Gravis

    phase 3 mab active

    1 trial

  22. Telitacicept

    Vor Biopharma

    Primary Sjogren's Disease

    phase 3 mab active

    1 trial

  23. Telitacicept

    Vor Biopharma

    Systemic Lupus Erythematosus

    phase 3 mab terminated

    2 trials

  24. Telmisartan/Amlodipine

    Dong Wang

    Hypertension With Hyperlipidemia

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources